You are here: Industry Insights > STING

News List

Lilly and Verge Genomics partner to use AI for drug development pharmaceutical-technology
July 12, 2021
Eli Lilly has entered a three-year partnership with biotech company Verge Genomics to research and create new drugs for the treatment of amyotrophic lateral sclerosis (ALS), a motor neuron disease.
Bayer enlists Curadev in STING antagonist collaboration pharmatimes
March 26, 2020
Bayer and Curadev have announced a novel research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program.
Bayer signs drug development and licensing deal with Curadev pharmaceutical-technology
March 25, 2020
German healthcare company Bayer has entered into a research collaboration and licence agreement with India-based drug discovery firm Curadev.
Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications expresspharma
March 24, 2020
The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.
Lilly, Aduro Biotech Announce Research Collaboration, License Agreement americanpharmaceuticalreview
December 20, 2018
Eli Lilly and Company and Aduro Biotech announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway Inhibitor program for .....
Frazier-Backed Mavupharma Scores $20M to Fund STING Program biospace
November 30, 2017
Frazier-backed Mavupharma secures $20M in Series A financing to fund STING program